Scalper1 News
Valeant Pharmaceuticals International (VRX) officially launched its hostile bid for Allergan on Wednesday, while one analyst speculated that Allergan might counterattack with a tax-inversion acquisition of its own. Valeant took directly to shareholders the sweetened bid for Allergan it unveiled on May 30, amounting to $72 a share in cash plus 0.83 Valeant share per Allergan share. Allergan (AGN) directors rejected that offer, like all of Valeant’s Scalper1 News
Scalper1 News